17 completed, 1 recruiting, 1 withdrawn. 5 Phase 3, 4 Phase 1, 4 Phase 2, 3 Phase 4, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
| Phase 1 | 4 | Completed 3, Withdrawn 1 |
| Phase 2 | 4 | Completed 4 |
| Phase 4 | 3 | Completed 2, Recruiting 1 |
| Not applicable | 2 | Completed 2 |
Follow Gabapentin Enacarbil: new trials by email Literature Review of Gabapentin Enacarbil trials Research Report on Gabapentin Enacarbil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease Gabapentin Enacarbil, Placebo Oral Tablet - Alzheimer Disease | Phase 4 | Recruiting | University of Texas at Austin | 156 | 2017-07-01 | 2022-05-18 |
| A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients Placebo, Gabapentin enacarbil - Restless Legs Syndrome (RLS) | Phase 4 | Completed | Astellas Pharma Inc | 375 | 2017-03-30 | 2024-12-12 |
| The Effect of Horizant (Gabapentin Enacarbil) on Augmentation Horizant - Restless Legs Syndrome | Not applicable | Completed | University of Missouri-Columbia | 10 | 2016-01-01 | 2022-02-24 |
| A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS HORIZANT 300 mg - RLS | Phase 1 | Withdrawn | XenoPort, Inc. | 2016-01-01 | 2021-04-12 | |
| Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores Gabapentin enacarbil, Placebo - Pain | Not applicable | Completed | The Cleveland Clinic | 107 | 2016-01-01 | 2024-01-09 |
| HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder gabapentin enacarbil, Placebo - Alcohol Use Disorder | Phase 2 | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 346 | 2015-06-01 | 2018-11-14 |
| Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment Gabapentin enacarbil - Restless Legs Syndrome (RLS) | Phase 4 | Completed | Astellas Pharma Inc | 19 | 2013-11-05 | 2024-11-08 |
| Specified Drug Use-Results Survey of Regnite Regnite - Restless Legs Syndrome | Completed | Astellas Pharma Inc | 1597 | 2012-10-01 | 2019-04-29 | |
| Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects gabapentin enacarbil, diphenhydramine, placebo - Restless Legs Syndrome (RLS) | Phase 1 | Completed | XenoPort, Inc. | 36 | 2011-06-01 | 2013-07-16 |
| ASP8825 - A Study to Investigate the Food Effect on the Pharmacokinetics of ASP8825 ASP8825 - Healthy Volunteers | Phase 1 | Completed | Astellas Pharma Inc | 18 | 2009-01-01 | 2015-12-16 |
| Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance GSK1838262 Extended Release Tablets, Placebo - Restless Legs Syndrome, Restless Legs Syndrome (RLS) | Phase 3 | Completed | XenoPort, Inc. | 136 | 2008-10-01 | 2013-07-22 |
| A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment GEn 1200mg/day, GEn 3600mg/day - Neuralgia, Postherpetic | Phase 2 | Completed | XenoPort, Inc. | 96 | 2008-03-01 | 2013-07-22 |
| A Study In Patients With Neuropathic Pain From Diabetic Peripheral Neuropathy (DPN) Placebo, GEn 1200mg/day, GEn 2400mg/day - Neuropathy, Diabetic | Phase 2 | Completed | XenoPort, Inc. | 421 | 2008-03-01 | 2013-07-22 |
| A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN) GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day - Neuralgia, Postherpetic | Phase 2 | Completed | XenoPort, Inc. | 376 | 2008-02-01 | 2013-07-22 |
| ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis ASP8825 - Patients With Impaired Renal Function and Haemodialysis | Phase 1 | Completed | Astellas Pharma Inc | 18 | 2008-02-01 | 2016-02-04 |
| Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients ASP8825 - Restless Legs Syndrome | Phase 3 | Completed | Astellas Pharma Inc | 182 | 2007-12-01 | 2016-02-04 |
| XP13512 vs. Placebo in Patients With Restless Legs Syndrome. XP13512 600MG, XP13512 1200MG, PLACEBO - Restless Legs Syndrome | Phase 3 | Completed | XenoPort, Inc. | 325 | 2006-08-01 | 2013-07-22 |
| XP13512 (Gabapentin Enacarbil) Extension Study in Patients With Restless Legs Syndrome. XP13512 (GEn) - Restless Legs Syndrome | Phase 3 | Completed | XenoPort, Inc. | 581 | 2006-06-01 | 2013-07-22 |
| Long-Term Study of Gabapentin Enacarbil (GEn, XP13512) vs. Placebo in Patients With Restless Legs Syndrome. GEn (XP13512), Placebo - Restless Legs Syndrome | Phase 3 | Completed | XenoPort, Inc. | 327 | 2006-04-01 | 2013-07-22 |
Restless Legs Syndrome (11) · Neuralgia (3) · Neuralgia, Postherpetic (2) · Alcohol Drinking (1) · Alcoholism (1) · Alzheimer Disease (1) · Diabetic Neuropathies (1) · Pain (1) · Parasomnias (1) · Renal Insufficiency (1)
XenoPort, Inc. (9) · Astellas Pharma Inc (6) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (1) · The Cleveland Clinic (1) · University of Missouri-Columbia (1) · University of Texas at Austin (1)
United States (10) · Japan (6) · Canada (1) · Germany (1)
Daniel Sessler, M.D. (1) · Kathy Richards, PhD (1) · Pradeep Sahota, MD (1) · Raye Z. Litten, Ph.D. (1) · Steven Caras, MD (1)
PMID 21527006, PMID 21677899, PMID 23186035, PMID 24102928, PMID 26788345, PMID 27067343, PMID 27288210, PMID 32966585
R01AG051588 (1)